Should pregnant women with anticoagulant prophylaxis benefit from scheduled delivery?
Anticoagulants
Delivery
Heparin
Pregnancy
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
24
03
2020
accepted:
17
10
2020
pubmed:
11
11
2020
medline:
29
5
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
When vaginal delivery is considered in women with low-molecular-weight heparin (LMWH) treatment, epidural analgesia is contraindicated for 12-24 h after the last injection. We evaluated the proportion of epidural analgesia depending on whether this is scheduled delivery (labor induction after stopping LMWH) or unscheduled delivery (stopping LMWH at labor onset). Retrospective hospital study running from 2015 to 2017. Inclusion criteria for patients with LMWH treatment were: singleton pregnancy, gestational age ≥ 38 weeks of gestation and possible vaginal delivery. The primary endpoint was the epidural analgesia rate. Secondary endpoints included risks for caesarean section, deep vein thrombosis, and postpartum hemorrhage. Among 129 patients, 54 had scheduled delivery (41.9%). In practice, only 44 of them had labor induction (81.5%) and 54 of the 75 patients in the unscheduled delivery group had spontaneous delivery (72.0%). There was no significant difference in the rate of epidural analgesia between the "scheduled" and "unscheduled" groups (52/54 (96.3%) vs. 66/75 (88.0%) (p = 0.12)), and no difference in the secondary endpoints. High access rates to epidural analgesia are observed in both scheduled and unscheduled deliveries. Scheduled delivery does not appear to be a really advantageous strategy for women with LMWH prophylaxis.
Identifiants
pubmed: 33169233
doi: 10.1007/s00404-020-05850-6
pii: 10.1007/s00404-020-05850-6
doi:
Substances chimiques
Anticoagulants
0
Heparin, Low-Molecular-Weight
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1191-1196Références
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO et al (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S–e736S. https://doi.org/10.1378/chest.11-2300
doi: 10.1378/chest.11-2300
pubmed: 22315276
pmcid: 3278054
Bowyer L (2008) The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer 2003–2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the UK. Obstet Med 1(1):54–54. https://doi.org/10.1258/om.2008.080017
doi: 10.1258/om.2008.080017
pmcid: 5010105
Schutte J, Steegers E, Schuitemaker N, Santema J, de Boer K, Pel M et al (2010) Rise in maternal mortality in the Netherlands. BJOG Int J Obstet Gynaecol. 117:399–406
doi: 10.1111/j.1471-0528.2009.02382.x
Saucedo M, Deneux-Tharaux C, Bouvier-Colle M-H (2013) Maternal mortality in France, 2007–2009. J Gynecol Obstet Biol Reprod. 42:613–627
doi: 10.1016/j.jgyn.2013.06.011
Greer IA (2006) Anticoagulants in pregnancy. J Thromb Thrombolysis. 21:57–65
doi: 10.1007/s11239-006-5578-5
Deruelle P, Coulon C (2007) The use of low-molecular-weight heparins in pregnancy–how safe are they? Curr Opin Obstet Gynecol. 19:573–577
doi: 10.1097/GCO.0b013e3282f10e33
Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA et al (2003) Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med. 28:172–197
pubmed: 12772135
Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM et al (2010) Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 27:999–1015
doi: 10.1097/EJA.0b013e32833f6f6f
Collins J, Bowles L, MacCallum PK (2005) Prevention and management of venous thromboembolism in pregnancy. Br J Hosp Med Lond Engl 2016(120):S26-34
Lindqvist PG, Bremme K, Hellgren M, for the Swedish Society of Obstetrics and Gynecology (SFOG) Working Group on Hemostatic Disorders (Hem-ARG) (2011) Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism. Acta Obstet Gynecol Scand. 90:648–653
doi: 10.1111/j.1600-0412.2011.01098.x
Philippe A, Ruivard M, Auclair C, Accoceberry M, Bonnin M, Pouly J-L et al (2015) Anticoagulation and peripartum management. Gynecol Obstet Fertil. 71:322–329
Roueli A, Cesario E, Amsellem J, Agman A, Vauthier-Brouzes D, Nizard J (2017) Is a therapeutic anticoagulation window needed for delivery when using prophylactic low molecular weight heparin during pregnancy? A retrospective monocentric study. Eur J Obstet Gynecol Reprod Biol. 215:118–123
doi: 10.1016/j.ejogrb.2017.05.019
Boulvain M, Marcoux S, Bureau M, Fortier M, Fraser W (2001) Risks of induction of labour in uncomplicated term pregnancies. Paediatr Perinat Epidemiol. 15:131–138
doi: 10.1046/j.1365-3016.2001.00337.x
Cammu H, Martens G, Ruyssinck G, Amy J-J (2002) Outcome after elective labor induction in nulliparous women: a matched cohort study. Am J Obstet Gynecol. 186:240–244
doi: 10.1067/mob.2002.119643
Grobman WA et al (2018) Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med. 379(6):513–523
doi: 10.1056/NEJMoa1800566
Le Ray C, Carayol M, Bréart G, Goffinet F, PREMODA Study Group (2007) Elective induction of labor: failure to follow guidelines and risk of cesarean delivery. Acta Obstet Gynecol Scand. 86:657–665
doi: 10.1080/00016340701245427
Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C et al (2001) Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG Int J Obstet Gynaecol. 108:1134–1140
doi: 10.1111/j.1471-0528.2003.00272.x
Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E et al (1999) Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 81:668–672
doi: 10.1055/s-0037-1614550
Weitz JI (1997) Low-Molecular-Weight Heparins. N Engl J Med. 337:688–699
doi: 10.1056/NEJM199709043371007
Bara L, Samama M (1988) Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl. 543:65
pubmed: 2847460
Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C et al (2005) Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost JTH. 3:949–954
doi: 10.1111/j.1538-7836.2005.01307.x
De Stefano V, Martinelli I, Rossi E, Battaglioli T, Za T, Mannuccio Mannucci P et al (2006) The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol. 135:386–391
doi: 10.1111/j.1365-2141.2006.06317.x
Henderson J, Redshaw M (2013) Women’s experience of induction of labor: a mixed methods study. Acta Obstet Gynecol Scand. 92:1159–1167
pubmed: 23808325
Bates SM et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2:3317–3359
doi: 10.1182/bloodadvances.2018024802